insulin glargine biosimilar Semglee
Selected indexed studies
- The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn. (J Diabetes Sci Technol, 2023) [PMID:34971335]
- [New Insulins for Type 1 Diabetes treatment]. (Andes Pediatr, 2023) [PMID:37909930]
- Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation. (JAMA Health Forum, 2025) [PMID:40314944]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- MYL1501D Insulin Glargine: A Review in Diabetes Mellitus. (2020) pubmed
- The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn. (2023) pubmed
- [New Insulins for Type 1 Diabetes treatment]. (2023) pubmed
- Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation. (2025) pubmed
- [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. (2018) pubmed
- Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine. (2024) pubmed
- Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study. (2025) pubmed
- Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries. (2025) pubmed
- In brief: Semglee - insulin glargine interchangeable with Lantus. (2021) pubmed
- Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine. (2021) pubmed